Sailong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 26, 2022 at 08:54 am EDT
Share
Sailong Pharmaceutical Group Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 62.21 million compared to CNY 68.29 million a year ago. Revenue was CNY 62.21 million compared to CNY 68.29 million a year ago. Net income was CNY 1.28 million compared to CNY 2.06 million a year ago. Basic earnings per share from continuing operations was CNY 0.0073 compared to CNY 0.0117 a year ago. Diluted earnings per share from continuing operations was CNY 0.0073 compared to CNY 0.0117 a year ago.
Sailong Pharmaceutical Group Co Ltd, formerly Zhuhai Sailong Pharmaceutical Co Ltd, is a China-based company principally engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations, as well as providing technical services. The Companyâs main products include monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others. Through its subsidiaries, the Company is also engaged in the sales of scraps, provision of technical services and sales promotion. The Company mainly conducts its businesses with domestic market.
SAILONG PHARMACEUTICAL GROUP CO.,LTD. 
